Zhou Caicun, Wang Jie, Wang Baocheng, Cheng Ying, Wang Zhehai, Han Baohui, Lu You, Wu Gang, Zhang Li, Song Yong, Zhu Bo, Hu Yi, Wang Ziping, Song Qibin, Ren Shengxiang, He Yayi, Hu Xiaohua, Zhang Jian, Yao Yu, Zhao Hongyun, Wang Zhijie, Chu Qian, Duan Jianchun, Liu Jingjing, Qin Shukui
Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China.
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Zhongguo Fei Ai Za Zhi. 2021 Apr 20;24(4):217-235. doi: 10.3779/j.issn.1009-3419.2021.101.13. Epub 2021 Apr 26.
Non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer. The systemic antitumor therapy of advanced NSCLC has undergone renovations of chemotherapy, targeted therapy and immunotherapy, which results in greatly improved survival for patients with advanced NSCLC. Immune checkpoint inhibitors (ICIs), especially targeting programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1), has changed the treatment paradigm of NSCLC. ICIs have become the standard treatment for advanced NSCLC without epidermal growth factor receptor(EGFR) mutation or anaplastic lymphomakinase(ALK) translocation in the first- or second-line setting, and for locally advanced NSCLC following concurrent radiotherapy and chemotherapy. ICIs are also promising in adjuvant/neoadjuvant therapy. More and more ICIs have been approved domestically for the treatment of NSCLC. Led by the NSCLC expert committee of Chinese Society of Clinical Oncology (CSCO), this consensus was developed and updated based on thoroughly reviewing domestic and foreign literatures, clinical trial data, systematic reviews, experts' discussion and the consensus(2019 version). This consensus will aid domestic clinicians in the treatment of NSCLC with ICIs. .
非小细胞肺癌（NSCLC）是肺癌最常见的病理类型。晚期NSCLC的全身抗肿瘤治疗经历了化疗、靶向治疗和免疫治疗的革新，这使得晚期NSCLC患者的生存期得到了显著改善。免疫检查点抑制剂（ICIs），尤其是针对程序性细胞死亡蛋白1（PD-1）/程序性死亡配体1（PD-L1）的抑制剂，已经改变了NSCLC的治疗模式。ICIs已成为一线或二线治疗中无表皮生长因子受体（EGFR）突变或间变性淋巴瘤激酶（ALK）易位的晚期NSCLC，以及同步放化疗后局部晚期NSCLC的标准治疗方法。ICIs在辅助/新辅助治疗中也很有前景。越来越多的ICIs在国内被批准用于治疗NSCLC。本共识由中国临床肿瘤学会（CSCO）NSCLC专家委员会牵头，在全面回顾国内外文献、临床试验数据、系统评价、专家讨论以及2019版共识的基础上制定并更新。本共识将有助于国内临床医生使用ICIs治疗NSCLC。
